SİKLOFOSFAMİD- KARMUSTİN- ETOPOSİD (CBV) OTOLOG KÖK HÜCRE NAKLİ HAZIRLIK PROTOKOLÜ

Kaynaklar:

1-Hensley ML, Hagerty KL, Kewalramani T et al. 2009 " American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants". J Clin Oncol. Jan 1;27(1):127-45.

2-Apperley J, Carreras E, Gluckman E, et al. 2012. "The EBMT-ESH Handbook: Haematopoietic Stem Cell Transplantation". Sixth Edition.

3-Bressler RB and Huston DP 1985. "Water intoxication following moderate-dose intravenous cyclophosphamide." Arch Intern Med Mar;145(3):548-9.

4-Stiff PJ, Dahlberg S, Forman SJ et al. 1998 " Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial".J Clin Oncol. Jan;16(1):48-55.

5-Salar A, Sierra J, Gandarillas M et al. 2001"Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens" Bone Marrow Transplant. Feb;27(4):405-12.

6-Robertson, M. J., R. Abonour, R. Hromas, et al. 2005. "Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma." Leuk Lymphoma 46(10):1477-1487.

7-Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997 Feb 1;89(3):801-13.

8-Lazarus, H. M., F. R. Loberiza, Jr., M. J. Zhang, et al. 2001. "Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)." Bone Marrow Transplant 27(4):387-396.

9-Wheeler, C., A. Khurshid, J. Ibrahim, et al. 2001. "Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV)." Leuk Lymphoma 40(5-6):499-509.

10-Lane, A. A, P. Armand, Y. Feng, et al. 2012. "Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant." Leuk Lymphoma 53(6):1130-1136

11-Puig, N., De La Rubia, J., Remigia M, et al. 2006. "Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation." Leukemia and Lymphoma. Aug;47(8):1488-94.